Hospital
Oakwood Healthcare, INC.
Oakwood Healthcare, INC. was paid $23.26M by Medicaid between Jan 2018 and Dec 2024, across 242 billing codes. Its largest line is 99285, emergency room visit (most serious) — 44% of everything it billed.
33Billing provider infoOAKWOOD HEALTHCARE, INC.
TRENTON, MI 48183
TRENTON, MI 48183
33aNPI1740230648assigned 05/11/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$23.26M
24GClaims550,460
24DCodes billed242
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#42 of 86
Median peer was paid$21.55M
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official COX, MATTHEW controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 67,307 | $2.58M | |
| 2019 | 65,679 | $2.54M | |
| 2020 | 60,767 | $2.59M | |
| 2021 | 82,187 | $3.51M | |
| 2022 | 91,468 | $4.12M | |
| 2023 | 101,578 | $4.56M | |
| 2024incomplete | 81,474 | $3.35M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 44% | 33,706 | 31,011 | $10.33M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.6% | 9,615 | 9,341 | $1.77M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.5% | 17,480 | 16,273 | $1.52M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 5,578 | 5,451 | $793K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.2% | 5,590 | 5,478 | $737K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 3.1% | 1,129 | 1,102 | $716K |
| G0378 | Hospital observation service, per hour | 3.0% | 4,743 | 4,215 | $696K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 4,771 | 4,645 | $437K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 14,534 | 12,366 | $359K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 9,314 | 8,034 | $344K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 5,738 | 5,611 | $338K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.4% | 5,083 | 4,345 | $325K |
230 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 3,964 | $321K |
| 93975 | 1.3% | 2,859 | $311K | |
| 71045 | Radiologic examination, chest; single view | 1.2% | 7,218 | $291K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.2% | 745 | $276K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.0% | 7,510 | $237K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,940 | $193K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,493 | $171K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 683 | $161K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,610 | $157K |
| 82947 | <1% | 3,002 | $152K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 261 | $152K |
| 76830 | Ultrasound, transvaginal | <1% | 2,484 | $146K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,004 | $143K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,932 | $141K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,449 | $138K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,874 | $132K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,029 | $125K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,931 | $101K |
| 76642 | <1% | 2,447 | $99K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,181 | $88K |
| 76801 | <1% | 1,358 | $83K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 838 | $76K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,606 | $71K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,925 | $70K |
| 76770 | <1% | 972 | $61K | |
| 72141 | <1% | 476 | $61K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,427 | $59K |
| 77066 | Tomosynthesis, mammo | <1% | 900 | $53K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 670 | $52K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 260 | $50K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,780 | $49K |
| 80061 | Lipid panel | <1% | 223 | $46K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 516 | $41K |
| 77065 | Tomosynthesis, mammo | <1% | 883 | $40K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 18,340 | $35K |
| 93971 | <1% | 730 | $35K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 525 | $27K |
| 72131 | <1% | 493 | $26K | |
| 97162 | <1% | 201 | $25K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,873 | $25K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,674 | $22K |
| 97161 | <1% | 421 | $21K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,871 | $21K |
| 93970 | <1% | 202 | $19K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,582 | $16K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,192 | $15K |
| 59025 | Fetal non-stress test | <1% | 149 | $14K |
| 74018 | <1% | 529 | $12K | |
| 87428 | <1% | 431 | $12K | |
| 74022 | <1% | 841 | $12K | |
| 73130 | <1% | 732 | $12K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 374 | $11K |
| 73630 | <1% | 746 | $11K | |
| 70486 | <1% | 293 | $10K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 26 | $10K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 965 | $9K |
| 76536 | <1% | 162 | $8K | |
| 71271 | <1% | 139 | $8K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 596 | $8K |
| 71250 | <1% | 169 | $8K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,248 | $7K |
| 72110 | <1% | 208 | $7K | |
| 80053 | Comprehensive metabolic panel | <1% | 14,729 | $7K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 54 | $7K |
| 86900 | <1% | 2,465 | $6K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 485 | $6K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 173 | $6K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,932 | $5K |
| 73564 | <1% | 145 | $5K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 281 | $5K |
| 73610 | <1% | 418 | $5K | |
| 76881 | <1% | 70 | $4K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 33,176 | $4K |
| 73030 | <1% | 540 | $4K | |
| 97014 | <1% | 441 | $3K | |
| 70491 | <1% | 29 | $3K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 25 | $2K |
| 93017 | <1% | 297 | $2K | |
| 74174 | <1% | 13 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 330 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 316 | $2K |
| 73221 | <1% | 12 | $2K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,430 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,629 | $2K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 798 | $2K |
| 91200 | <1% | 25 | $2K | |
| 81025 | <1% | 6,792 | $1K | |
| 87631 | <1% | 1,186 | $1K | |
| 75574 | <1% | 15 | $1K | |
| 76882 | <1% | 27 | $1K | |
| 86850 | <1% | 2,443 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,448 | $940.67 |
| 97166 | <1% | 26 | $913.88 | |
| 82565 | <1% | 1,735 | $799.70 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 15 | $798.19 |
| 93880 | <1% | 12 | $678.33 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 477 | $647.53 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,634 | $645.25 |
| 73562 | <1% | 101 | $631.60 | |
| 96367 | <1% | 67 | $557.43 | |
| 85610 | <1% | 23,660 | $545.09 | |
| 72170 | <1% | 437 | $509.06 | |
| 83615 | <1% | 1,036 | $502.98 | |
| 87070 | <1% | 484 | $492.44 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 243 | $441.67 |
| 73110 | <1% | 36 | $401.91 | |
| 83735 | <1% | 12,624 | $397.21 | |
| 81001 | <1% | 8,869 | $386.76 | |
| 83690 | <1% | 12,142 | $376.33 | |
| 84450 | <1% | 704 | $367.13 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 434 | $364.14 |
| 84460 | <1% | 688 | $358.66 | |
| 84702 | <1% | 2,729 | $351.88 | |
| 70496 | <1% | 16 | $342.89 | |
| 85730 | <1% | 10,365 | $331.12 | |
| 86901 | <1% | 2,341 | $324.99 | |
| 81003 | <1% | 9,818 | $324.71 | |
| 73502 | <1% | 38 | $287.89 | |
| 84520 | <1% | 923 | $280.61 | |
| 84439 | <1% | 400 | $248.98 | |
| 84484 | <1% | 11,272 | $214.35 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 91 | $163.37 |
| 80305 | <1% | 1,705 | $147.50 | |
| 80051 | <1% | 484 | $138.81 | |
| 76870 | <1% | 29 | $122.26 | |
| 85027 | <1% | 1,447 | $120.62 | |
| 70498 | <1% | 19 | $100.63 | |
| 73590 | <1% | 55 | $96.96 | |
| 84478 | <1% | 32 | $83.36 | |
| 84100 | <1% | 2,377 | $68.68 | |
| 87077 | <1% | 103 | $64.99 | |
| 82962 | <1% | 2,222 | $62.80 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,580 | $55.54 |
| 83880 | <1% | 559 | $52.92 | |
| 85379 | <1% | 1,252 | $49.85 | |
| 80076 | <1% | 778 | $43.25 | |
| 73080 | <1% | 12 | $33.17 | |
| 87040 | <1% | 712 | $31.16 | |
| 82728 | <1% | 43 | $30.67 | |
| 82150 | <1% | 497 | $29.90 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,480 | $29.66 |
| 87186 | <1% | 50 | $24.42 | |
| 82550 | <1% | 315 | $22.43 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 613 | $21.99 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,675 | $21.69 |
| 96376 | <1% | 4,513 | $20.19 | |
| 82248 | <1% | 1,406 | $18.63 | |
| 86140 | <1% | 183 | $18.29 | |
| 88304 | <1% | 51 | $16.25 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 196 | $14.12 |
| 84550 | <1% | 14 | $14.09 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,740 | $11.99 |
| 82374 | <1% | 403 | $11.60 | |
| 84156 | <1% | 14 | $11.44 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,626 | $11.44 |
| 84295 | <1% | 408 | $11.40 | |
| 84132 | <1% | 451 | $10.82 | |
| 82435 | <1% | 403 | $10.82 | |
| 85652 | <1% | 198 | $9.93 | |
| 87081 | <1% | 670 | $9.34 | |
| 87430 | <1% | 688 | $9.30 | |
| 83605 | <1% | 2,106 | $8.83 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 2,938 | $6.49 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,081 | $5.38 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 133 | $5.30 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 801 | $3.47 |
| 87205 | <1% | 27 | $3.13 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,216 | $2.21 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,072 | $2.02 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,182 | $1.41 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,062 | $0.83 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 935 | $0.01 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 875 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 48 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 6,899 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 4,734 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 206 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 1,206 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 236 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 457 | $0.00 |
| 90715 | 0% | 824 | $0.00 | |
| 87400 | 0% | 520 | $0.00 | |
| 84145 | 0% | 427 | $0.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 874 | $0.00 |
| 80143 | 0% | 329 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 118 | $0.00 |
| 80179 | 0% | 322 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 113 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 119 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 142 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 34 | $0.00 |
| 87420 | 0% | 212 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 88 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 12 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 14 | $0.00 |
| 84155 | 0% | 12 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 12 | $0.00 |
| 85384 | 0% | 16 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 177 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 4,179 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 2,471 | $0.00 |
| 97010 | 0% | 1,782 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 5,968 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 1,261 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 325 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 208 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 56 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 12 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 98 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 202 | $0.00 |
| J3490 | Unclassified drugs | 0% | 302 | $0.00 |
| C1769 | Guide wire | 0% | 151 | $0.00 |
| A9573 | Injection, gadopiclenol, 1 ml | 0% | 181 | $0.00 |
| 94760 | 0% | 835 | $0.00 | |
| 82077 | 0% | 194 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 144 | $0.00 |
| 86308 | 0% | 303 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 253 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 58 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 33 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 38 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 57 | $0.00 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 0% | 13 | $0.00 |
| 85018 | 0% | 16 | $0.00 | |
| 88307 | 0% | 17 | $0.00 | |
| 84134 | 0% | 17 | $0.00 | |
| 73090 | 0% | 24 | $0.00 | |
| 76377 | 0% | 12 | $0.00 | |
| 88342 | 0% | 43 | $0.00 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 41 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOX, MATTHEW (CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.